Corrigendum: A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors (Future Medicinal Chemistry (2013) 5: 17 (2019-2035) DOI: 10.4155/fmc.13.166);A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors

Future Medicinal Chemistry

Volumn 5, Issue 17, 2013, Pages 2019-2035

  Maluf, Fernando V ^a   Andricopulo, Adriano D ^a   Oliva, Glaucius ^a   Guido, Rafael Vc ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 PYRAZOLYL ETHANONE DERIVATIVE; 1,3 DIOXOISOINDOLINE DERIVATIVE; 4 AMINO THIOPHEN DERIVATIVE; ANTITRYPANOSOMAL AGENT; INDOLEACETIC ACID; TRYPANOSOMA CRUZI GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE INHIBITOR; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; CHAGAS DISEASE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA CRUZI; VIRTUAL REALITY;

AMINO ACID SEQUENCE; CHAGAS DISEASE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84887935819     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.213     Document Type: Erratum

References (53)

1. Hotez P, Molyneux DH, Fenwick A et al. Control of neglected tropical diseases. N. Engl. J. Med. 357(10), 1018-1027 (2007). (Pubitemid 47367081)
2. Callan B, Gillespie I. The path to new medicines. Nature 449(7159), 164-165 (2007). (Pubitemid 47402354)
3. Coles LD, Cloyd JC The role of academic institutions in the development of drugs for rare and neglected diseases. Clin. Pharmacol. Ther. 92(2), 193-202 (2012).
4. Moran M, Guzman J, Ropars A.L., Illmer A. The role of product development partnerships in research and development for neglected diseases. Int. Health 2(2), 114-122 (2010).
5. Rassi A, Marin-Neto JA.Chagas disease. Lancet 375(9723), 1388-1402 (2010).
6. Yun O, Lima MA, Ellman T et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. PLoS Neglect. Trop. Dis. 3(7), e488 (2009).
7. Chagas C. Nova tripanossomíase humana. Estudos sobre a morfologia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., agente etiológico de nova entidade mórbida do homem. Mem. Inst. Oswaldo Cruz. 1(2), 159-218 (1909).
8. Duschak VG, Couto AS An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat. Antiinfect. Drug Discov. 2(1), 19-51 (2007). (Pubitemid 46729086)
9. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 115(1-2), 55-68 (2010).
10. Guido RVC, Oliva G. Structure-based drug discovery for tropical diseases. Curr. Top. Med. Chem. 9(9), 824-843 (2009).
11. Verlinde CL, Hannaert V, Blonski C et al. Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resist. Update. 4(1), 50-65 (2001). (Pubitemid 32267825)
12. Cáceres A.J., Michels PAM, Hannaert V. Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. Mol. Biochem. Parasitol. 169(1), 50-54 (2010).
13. Guido RVC, Oliva G, Andricopulo AD Modern drug discovery technologies: opportunities and challenges in lead discovery. Comb. Chem. High Throughput Screen 14(10), 830-839 (2011).
14. Guido RVC, Oliva G, Andricopulo AD Structure- and ligand-based drug design approaches for neglected tropical diseases. Pure Appl. Chem. 84(9), 1857-1866 (2012).
15. Ferreira RS, Guido RV, Andricopulo A.D., Oliva G. In silico screening strategies for novel inhibitors of parasitic diseases. Expert Opin. Drug Discov. 6(5), 481-489 (2011).
16. Guido RVC, Oliva G, Andricopulo AD Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem. 15(1), 37-46 (2008). (Pubitemid 351234626)
17. Postigo MP, Guido RVC, Oliva G et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J. Chem. Inf. Model. 50(9), 1693-1705 (2010).
18. Guido RVC, Balliano TL, Andricopulo A.D., Oliva G. Kinetic and crystallographic studies on glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi in complex with iodoacetate. Lett. Drug Des. Discov. 6(3), 210-214 (2009).
19. Guido RVC, Cardoso CL, Moraes MC de, Andricopulo AD, Cass QB, Oliva G. Structural insights into the molecular basis responsible for the effects of immobilization on the kinetic parameters of glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi and human. J. Braz. Chem. Soc. 21(10), 1845-1853 (2010).
20. Guido RVC, Oliva G, Montanari C.A., Andricopulo AD Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: molecular docking and 3D QSAR studies. J. Chem. Inf. Model. 48(4), 918-929 (2008). (Pubitemid 351757757)
21. Souza DH, Garratt RC, Araújo AP et al. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett. 424(3), 131-135 (1998). (Pubitemid 28135298)
22. Pavão F., Castilho MS, Pupo MT et al. Structure of Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase complexed with chalepin, a natural product inhibitor, at 1 A resolution. FEBS Lett. 520(1-3), 13-17 (2002). (Pubitemid 34607265)
23. Castilho MS, Pavão F, Oliva G., Ladame S, Willson M, Périé J. Evidence for the two phosphate binding sites of an analogue of the thioacyl intermediate for the Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase-catalyzed reaction, from its crystal structure. Biochemistry 42(23), 7143-7151 (2003). (Pubitemid 36706497)
24. Bressi JC, Verlinde CL, Aronov AM et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J. Med. Chem. 44(13), 2080-2093 (2001). (Pubitemid 32861769)
25. Aronov AM, Verlinde CL, Hol W.G., Gelb MH Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. J. Med. Chem. 41(24), 4790-4799 (1998). (Pubitemid 28530455)
26. Aronov AM, Suresh S, Buckner FS et al. Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl Acad. Sci. USA 96(8), 4273-4278 (1999). (Pubitemid 29190326)
27. + analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Bioorg. Med. Chem. Lett. 11(2), 95-98 (2001). (Pubitemid 32101441)
28. Davis AM, Teague SJ, Kleywegt GJ Application and limitations of x-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. Engl. 42(24), 2718-2736 (2003). (Pubitemid 36813974)
29. Irwin JJ, Sterling T, Mysinger M.M., Bolstad ES, Coleman RG ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757-1768 (2012).
30. Ladame S, Castilho MS, Silva CHTP et al. Crystal structure of Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase complexed with an analogue of 1,3-bisphospho-D-glyceric acid. Eur. J. Biochem. 270(22), 4574-4586 (2003). (Pubitemid 37452534)
31. Bruno IJ, Cole JC, Lommerse J.P., Rowland RS, Taylor R, Verdonk ML IsoStar: a library of information about nonbonded interactions. J. Comput. Aided Mol. Des. 11(6), 525-537 (1997). (Pubitemid 127506747)
32. Brenk R, Klebe G. 'Hot Spot' Analysis of Protein-binding Sites as a Prerequisite for Structure-based Virtual Screening and Lead Optimization In: Pharmacophores and Pharmacophore Searches (Volume 32) Langer T, Hoffmann RD (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2006).
33. Sotriffer C, Klebe G. Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. Farmaco 57(3), 243-251 (2002). (Pubitemid 38365952)
34. Gohlke H, Hendlich M, Klebe G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2(2), 337-356 (2000). (Pubitemid 30045364)
35. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28(7), 849-857 (1985). (Pubitemid 15012490)
36. Hindle SA, Rarey M, Buning C., Lengaue T. Flexible docking under pharmacophore type constraints. J. Comput. Aided Mol. Des. 16(2), 129-149 (2002). (Pubitemid 34855039)
37. Rarey M, Kramer B, Lengauer T., Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261(3), 470-489 (1996). (Pubitemid 26335901)
38. Pereira JM, Severino R P, Vieira PC et al. Anacardic acid derivatives as inhibitors of glyceraldehyde-3-phosphate dehydrogenase from Trypanosoma cruzi. Bioorg. Med. Chem. 16(19), 8889-8888 (2008).
39. McGovern SL, Helfand BT, Feng B, Shoichet BK A specific mechanism of nonspecific inhibition. J. Med. Chem. 46(20), 4265-4272 (2003). (Pubitemid 37153008)
40. Leitão A., Andricopulo AD, Oliva G et al. Structure-activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase. Bioorg. Med. Chem. Lett. 14(9), 2199-2204 (2004). (Pubitemid 38481390)
41. De Marchi A.A., Castilho MS, Nascimento PGB et al. New 3-piperonylcoumarins as inhibitors of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from Trypanosoma cruzi. Bioorg. Med. Chem. 12(18), 4823-4833 (2004). (Pubitemid 39164390)
42. Macedo EMS d.e., Wiggers HJ, Silva MGV, Braz-Filho R, Andricopulo AD, Montanari CA A new bianthron glycoside as inhibitor of Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase activity. J. Braz. Chem. Soc. 20(5), 947-953 (2009).
43. Freitas R.F., Prokopczyk IM, Zottis A et al. Discovery of novel Trypanosoma cruzi glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorg. Med. Chem. 17(6), 2476-2482 (2009).
44. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44(1), 235-249 (2000). (Pubitemid 32239479)
45. Palm K, Stenberg P, Luthman K., Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res. 14(5), 568-571 (1997). (Pubitemid 27220272)
46. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today. 9(10), 430-431 (2004). (Pubitemid 38510559)
47. Oprea TI, Davis AM, Teague S.J., Leeson PD Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41(5), 1308-1315 (2001).
48. Jones G, Willet P, Glen RC et al. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267(3), 727-748 (1997). (Pubitemid 27170693)
49. Feher M. Consensus scoring for protein-ligand interactions. Drug Discov. Today. 11(9-10), 421-428 (2006). (Pubitemid 44382521)
50. Klebe G. Virtual Screening: Scope And Limitation. In: Virtual Screening in Drug Discovery (Volume 1). Alvarez J, Shoichet B (Eds). CRC Press, FL, USA, 3-24 (2005).
51. Hannaert V, Opperdoes FR, Michels PA Glycosomal glyceraldehyde-3- phosphate dehydrogenase of Trypanosoma brucei and Trypanosoma cruzi: expression in Escherichia coli, purification, and characterization of the enzymes. Protein Expr. Purif. 6(3), 244-250 (1995).
52. Gasteiger E, Gattiker A, Hoogland C., Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and ana lysis. Nucleic Acids Res. 31(13), 3784-3788 (2003). (Pubitemid 37442246)
53. ClustalW2. www.ebi.ac.uk/Tools/msa/clustalw2